Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

P. van Balen, MD, C.A.M. van Bergen, I. Jedema, PhD, S.A.P. van Luxemburg-Heijs, J.C. Harskamp, H.M. van Egmond, S.A.J. Veld, M. Griffioen, PhD, W.A.F. Marijt, MD, PhD, C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2012) 120 (21): 4116.

https://doi.org/10.1182/blood.V120.21.4116.4116

Published: 2012

Journal Articles

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

C.J.M. Halkes, MD, PhD, I Jedema, PhD, H.M. van Egmond, L van der Fits, PhD, J.H.F. Falkenburg, MD, PhD, MH Vermeer, MD, PhD

Blood (2011) 118 (21): 2491.

https://doi.org/10.1182/blood.V118.21.2491.2491

Published: 2011

Journal Articles

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD, H.M. van Egmond, J. Olde Wolbers, C.W.J. Starrenburg, P. van Balen, MD, M. van de Meent, P.A. von dem Borne, MD, PhD, W.A.F. Marijt, MD, PhD, J.H. Veelken, MD, PhD, I Jedema, PhD

Blood (2011) 118 (21): 1979.

https://doi.org/10.1182/blood.V118.21.1979.1979

Published: 2011

Journal Articles

HLA Class II Upregulation During An Ongoing Viral Infection Can Lead to HLA-DP Directed Graft-Versus-Host Disease After HLA-DPB1 Mismatched CD4+ Donor Lymphocyte Infusion

Sanja Stevanovic, MSc, Cornelis A.M. van Bergen, Simone A.P. van Luxemburg-Heijs, Jessica C. Harskamp, MD, C.J.M. Halkes, MD, PhD, Marieke Griffioen, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2011) 118 (21): 3062.

https://doi.org/10.1182/blood.V118.21.3062.3062

Published: 2011

Journal Articles

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

M. Eefting, MD, C.J.M. Halkes, MD, PhD, S. Kersting, MD, PhD, W.A.F. Marijt, MD, PhD, P.A. von dem Borne, MD, PhD, J.H. Veelken, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2011) 118 (21): 3064.

https://doi.org/10.1182/blood.V118.21.3064.3064

Published: 2011

Journal Articles

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

P.A. Von Dem Borne, MD, PhD, C.J.M. Halkes, MD, PhD, C.W.J. Starrenburg, W.A.F. Marijt, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2010) 116 (21): 2328.

https://doi.org/10.1182/blood.V116.21.2328.2328

Published: 2010

Journal Articles

First Line Treatment of Aggressive Cutaneous NK/T Cell Lymphomas Based on High Dose Cytarabine and Stem Cell Transplantation Does Not Lead to Durable Remissions.

C.J.M. Halkes, MD, M.H. Vermeer, MD, E.M. Noordijk, MD, R. Willemze, MD, Roelof Willemze, MD

Blood (2006) 108 (11): 4669.

https://doi.org/10.1182/blood.V108.11.4669.4669

Published: 2006

NARROW

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

HLA Class II Upregulation During An Ongoing Viral Infection Can Lead to HLA-DP Directed Graft-Versus-Host Disease After HLA-DPB1 Mismatched CD4+ Donor Lymphocyte Infusion

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

First Line Treatment of Aggressive Cutaneous NK/T Cell Lymphomas Based on High Dose Cytarabine and Stem Cell Transplantation Does Not Lead to Durable Remissions.

Email alerts

ASH Publications

American Society of Hematology

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

HLA Class II Upregulation During An Ongoing Viral Infection Can Lead to HLA-DP Directed Graft-Versus-Host Disease After HLA-DPB1 Mismatched CD4+ Donor Lymphocyte Infusion

Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion

Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft

First Line Treatment of Aggressive Cutaneous NK/T Cell Lymphomas Based on High Dose Cytarabine and Stem Cell Transplantation Does Not Lead to Durable Remissions.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only